Durata Therapeutics price target raised to $18 from $14 at JMP Securities JMP Securities increased its price target on Durata ahead of its evaluation of a single dose version of its dalbavancin anti-infection drug. The firm thinks that creating a single dose regimen for the drug will increase its market penetration beginning around 2017. JMP Securities reiterates an Outperform rating on the shares.
News For DRTX From The Last 14 Days
Check below for free stories on DRTX the last two weeks.